News
IFRX
2.100
+3.96%
0.080
Weekly Report: what happened at IFRX last week (0810-0814)?
Weekly Report · 5d ago
Here's Why We're Not At All Concerned With InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Simply Wall St · 08/11 11:06
Weekly Report: what happened at IFRX last week (0803-0807)?
Weekly Report · 08/10 09:10
InflaRx Price Target Raised to $6.00/Share From $4.00 by Cantor Fitzgerald
Dow Jones · 08/07 12:40
InflaRx Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 08/07 12:40
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6
Benzinga · 08/07 12:30
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), InflaRx (IFRX) and Tectonic Therapeutic (TECX)
TipRanks · 08/07 00:50
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
TipRanks · 08/06 21:20
InflaRx files $250M mixed securities shelf
TipRanks · 08/06 13:26
InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K
TipRanks · 08/06 12:29
InflaRx GAAP EPS of -€0.09
Seeking Alpha · 08/06 11:38
InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate
Benzinga · 08/06 11:33
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Barchart · 08/06 06:30
InflaRx Q2 2026 Earnings Preview
Seeking Alpha · 08/05 14:49
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
NASDAQ · 08/04 12:50
Weekly Report: what happened at IFRX last week (0727-0731)?
Weekly Report · 08/03 09:10
Weekly Report: what happened at IFRX last week (0720-0724)?
Weekly Report · 07/27 09:11
Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX) and Baxter International (BAX)
TipRanks · 07/27 07:40
Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Arcus Biosciences (RCUS)
TipRanks · 07/22 00:02
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 07/21 07:00
More
Webull provides a variety of real-time IFRX stock news. You can receive the latest news about Inflarx through multiple platforms. This information may help you make smarter investment decisions.
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.